Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Health plan utilization and costs of specialty drugs within 4 chronic conditions.

Gleason PP, Alexander GC, Starner CI, Ritter ST, Van Houten HK, Gunderson BW, Shah ND.

J Manag Care Pharm. 2013 Sep;19(7):542-8.

2.

Generic drug discount programs: are prescriptions being submitted for pharmacy benefit adjudication?

Tungol A, Starner CI, Gunderson BW, Schafer JA, Qiu Y, Gleason PP.

J Manag Care Pharm. 2012 Nov-Dec;18(9):690-700.

3.

Price increases and new drugs drive increased expenditures for multiple sclerosis.

Schafer JA, Gunderson BW, Gleason PP.

J Manag Care Pharm. 2010 Nov-Dec;16(9):713-7. No abstract available.

4.

Association of prescription abandonment with cost share for high-cost specialty pharmacy medications.

Gleason PP, Starner CI, Gunderson BW, Schafer JA, Sarran HS.

J Manag Care Pharm. 2009 Oct;15(8):648-58.

5.
6.

Are incentive-based formularies inversely associated with drug utilization in managed care?

Gleason PP, Gunderson BW, Gericke KR.

Ann Pharmacother. 2005 Feb;39(2):339-45. Epub 2005 Jan 11. Review.

PMID:
15644478
7.

Pharmacodynamics of pulse dosing versus standard dosing: in vitro metronidazole activity against Bacteroides fragilis and Bacteroides thetaiotaomicron.

Ibrahim KH, Gunderson BW, Hermsen ED, Hovde LB, Rotschafer JC.

Antimicrob Agents Chemother. 2004 Nov;48(11):4195-9.

8.

Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model.

Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC.

Antimicrob Agents Chemother. 2003 Mar;47(3):905-9.

9.
10.

Comparative pharmacodynamics of three newer fluoroquinolones versus six strains of staphylococci in an in vitro model under aerobic and anaerobic conditions.

Wright DH, Gunderson BW, Hovde LB, Ross GH, Ibrahim KH, Rotschafer JC.

Antimicrob Agents Chemother. 2002 May;46(5):1561-3.

11.

What do we really know about antibiotic pharmacodynamics?

Gunderson BW, Ross GH, Ibrahim KH, Rotschafer JC.

Pharmacotherapy. 2001 Nov;21(11 Pt 2):302S-318S. Review.

PMID:
11714222
12.

Pharmacokinetics of pilocarpine in subjects with varying degrees of renal function.

St Peter JV, Lambrecht LJ, Gunderson BW, Andersen SA, Gallagher SC, Swan SK.

J Clin Pharmacol. 2000 Dec;40(12 Pt 2):1470-5.

PMID:
11185668
13.

Retrospective analysis of cisapride-induced QT changes in end-stage renal disease patients.

Hentges MJ, Gunderson BW, Lewis MJ.

Nephrol Dial Transplant. 2000 Nov;15(11):1814-8.

PMID:
11071970

Supplemental Content

Loading ...
Support Center